| Literature DB >> 29937405 |
Chin-Yuan Chang1, Xiaohui Yan1, Ivana Crnovcic1, Thibault Annaval1, Changsoo Chang2, Boguslaw Nocek2, Jeffrey D Rudolf1, Dong Yang1, Gyorgy Babnigg3, Andrzej Joachimiak4, George N Phillips5, Ben Shen6.
Abstract
The enediynes, microbial natural products with extraordinary cytotoxicities, have been translated into clinical drugs. Two self-resistance mechanisms are known in the enediyne producers-apoproteins for the nine-membered enediynes and self-sacrifice proteins for the ten-membered enediyne calicheamicin. Here we show that: (1) tnmS1, tnmS2, and tnmS3 encode tiancimycin (TNM) resistance in its producer Streptomyces sp. CB03234, (2) tnmS1, tnmS2, and tnmS3 homologs are found in all anthraquinone-fused enediyne producers, (3) TnmS1, TnmS2, and TnmS3 share a similar β barrel-like structure, bind TNMs with nanomolar KD values, and confer resistance by sequestration, and (4) TnmS1, TnmS2, and TnmS3 homologs are widespread in nature, including in the human microbiome. These findings unveil an unprecedented resistance mechanism for the enediynes. Mechanisms of self-resistance in producers serve as models to predict and combat future drug resistance in clinical settings. Enediyne-based chemotherapies should now consider the fact that the human microbiome harbors genes encoding enediyne resistance.Entities:
Keywords: anthraquinone-fused enediyne; antibody-drug conjugate; anticancer drug; biosynthesis; enediyne; resistance; sequence similarity network; sequestration; the human microbiome; tiancimycin
Mesh:
Substances:
Year: 2018 PMID: 29937405 PMCID: PMC6208323 DOI: 10.1016/j.chembiol.2018.05.012
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 8.116